Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple ...

Nektar Therapeutics , a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its upsized underwritten ...

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industrial chain, announced that a recent clinical case report on its self-developed novel Nectin-4 ADC ...

Michael Levitt, the Nobel Laureate in Chemistry, recently arrived in Beijing and made a special trip to the office of Hu ...

No high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) was observed. Grade 3/4 neutropenia, a known AE associated with lymphodepletion and CAR ...